Aethlon Medical (NASDAQ:AEMD) Coverage Initiated by Analysts at StockNews.com

Analysts at StockNews.com began coverage on shares of Aethlon Medical (NASDAQ:AEMD) in a report issued on Saturday. The brokerage set a “sell” rating on the medical equipment provider’s stock.

Separately, HC Wainwright reissued a “buy” rating and set a $7.00 target price on shares of Aethlon Medical in a report on Monday, March 10th.

Aethlon Medical Stock Performance

Shares of AEMD stock opened at $0.35 on Friday. Aethlon Medical has a fifty-two week low of $0.24 and a fifty-two week high of $1.79. The firm has a market capitalization of $5.07 million, a PE ratio of -0.22 and a beta of 1.71. The stock’s 50-day simple moving average is $0.53 and its 200-day simple moving average is $0.50.

Aethlon Medical (NASDAQ:AEMD) last issued its quarterly earnings results on Wednesday, February 12th. The medical equipment provider reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.09. Sell-side analysts forecast that Aethlon Medical will post -0.73 earnings per share for the current year.

Institutional Trading of Aethlon Medical

A number of hedge funds have recently modified their holdings of the stock. Boothbay Fund Management LLC acquired a new position in Aethlon Medical in the fourth quarter valued at approximately $186,000. Virtu Financial LLC purchased a new position in shares of Aethlon Medical during the 4th quarter valued at approximately $81,000. Sassicaia Capital Advisers LLC purchased a new position in shares of Aethlon Medical during the 4th quarter valued at approximately $31,000. Allegiance Financial Group Advisory Services LLC acquired a new position in shares of Aethlon Medical in the 4th quarter valued at $26,000. Finally, Renaissance Technologies LLC purchased a new stake in Aethlon Medical during the fourth quarter worth $25,000. Hedge funds and other institutional investors own 1.99% of the company’s stock.

About Aethlon Medical

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.